McIntyre Roger S, Vagic Dragana, Swartz Shari A, Soczynska Joanna K, Woldeyohannes Hanna O, Voruganti Lakshmi P, Konarski Jakub Z
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
CNS Drugs. 2008;22(6):443-53. doi: 10.2165/00023210-200822060-00001.
Mood disorders may be conceptualized as progressive neurodegenerative disorders associated with cognitive decline. Novel treatments capable of preserving and/or enhancing cognitive function represent an area of priority for research in the future. Insulin, insulin-like growth factor (IGF)-1 and incretins may play a critical role in both physiological and pathophysiological processes of the CNS. An emerging paradigm regarding the pathophysiology of mood disorders posits that alterations in biological networks that mediate stress compromise optimal neuronal and glial function. A growing body of evidence indicates that central administration of insulin may enhance cognitive function in both healthy and cognitively impaired individuals. The neuroactive peptides, insulin, IGF-1 and incretins, or agents that facilitate their central effects (e.g. insulin-sensitizing agents), may constitute novel and possibly disease-modifying neurocognitive treatments.
情绪障碍可被视为与认知衰退相关的进行性神经退行性疾病。能够维持和/或增强认知功能的新型治疗方法是未来研究的重点领域。胰岛素、胰岛素样生长因子（IGF）-1和肠促胰岛素可能在中枢神经系统的生理和病理生理过程中发挥关键作用。一种关于情绪障碍病理生理学的新兴范式认为，介导应激的生物网络改变会损害最佳的神经元和神经胶质功能。越来越多的证据表明，中枢给予胰岛素可能增强健康个体和认知受损个体的认知功能。神经活性肽、胰岛素、IGF-1和肠促胰岛素，或促进其中枢作用的药物（如胰岛素增敏剂），可能构成新型的、可能具有疾病修饰作用的神经认知治疗方法。
